Patients with NSCLC harboring AHNAK2 mutations exhibit higher tumor mutation burden (TMB), indicating enhanced tumor immunogenicity, and these mutations are associated with an activated immune microenvironment, marked by increased immune cell infiltration and activation (55). Here, AHNAK2 is linked to non-small cell lung carcinoma.